HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Innate Pharma (NASDAQ:IPHA) and maintained a price target of $11.5.
May 15, 2024 | 10:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Innate Pharma and maintained a price target of $11.5, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like HC Wainwright & Co. suggests strong confidence in Innate Pharma's future performance, likely leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100